An NAD infusion appointment should begin well before a cannula is inserted. Understanding how NAD infusions are administered helps patients assess whether a service is clinically responsible, while giving providers a practical framework for safe delivery. The process involves assessment, appropriate clinical oversight, controlled intravenous administration and observation, rather than simply attaching a drip.
NAD, short for nicotinamide adenine dinucleotide, is a coenzyme involved in cellular energy metabolism. Intravenous NAD services are offered in some wellness and recovery settings, but treatment claims should be approached carefully. Evidence for many proposed uses remains limited, protocols are not standardised, and an infusion should not replace investigation or treatment for persistent fatigue, neurological symptoms, low mood or other medical concerns.
How NAD infusions are administered in clinical practice
The administration route is intravenous, meaning NAD is delivered into a vein through a peripheral cannula. The precise process differs according to the product, treatment plan, individual clinical factors and the provider’s written protocols. A reputable UK service should be able to explain each stage clearly, including what is known, what is uncertain and why a particular approach has been recommended.
Assessment, suitability and informed consent
Before treatment, a suitably qualified clinician should take a relevant medical history and review current symptoms, medicines, allergies and previous reactions to intravenous therapies. They may also assess observations such as blood pressure, pulse, oxygen saturation and temperature where clinically appropriate.
This assessment is not a formality. Symptoms such as ongoing exhaustion, palpitations, unexplained weight change, breathlessness or pain may need assessment through conventional healthcare routes before an elective infusion is considered. The clinician should also identify factors that may make intravenous treatment unsuitable or require additional precautions, such as poor venous access, a history of significant allergic reactions, certain cardiovascular conditions, pregnancy or breastfeeding, and acute illness. Suitability depends on the person and the proposed treatment, not on a generic online questionnaire alone.
Informed consent should cover the intended purpose of the infusion, the limitations of available evidence, possible side effects, alternatives and the likely practical experience. Patients should have time to ask questions and should not feel pressured to proceed. Consent is ongoing: a person can ask for the infusion to be paused or stopped at any point.
Product governance and preparation
NAD products can vary, so clinics should have clear arrangements for procurement, storage, preparation and traceability. In a UK clinical setting, the provider should be transparent about the product being used, its source, expiry date, batch details and the governance that supports its use. Where prescribing is required, this must be undertaken by an appropriate prescriber and within the relevant legal and professional framework.
Before administration, the practitioner should confirm the patient’s identity, check the treatment documentation and inspect the product in line with local procedures. Preparation should follow aseptic practice to reduce the risk of contamination. The NAD solution may be diluted according to the provider’s clinical protocol and compatibility guidance. It should not be mixed casually with other ingredients for convenience or marketing purposes.
Good documentation matters here. The record should identify what was administered, the amount and dilution used, the route, the start and finish times, the batch number, the practitioner involved and any observations or symptoms during treatment. This supports continuity of care and enables appropriate action if an adverse event is identified later.
Cannulation and starting the infusion
The practitioner usually inserts a small peripheral cannula into a suitable vein, commonly in the hand or arm. Skin preparation, hand hygiene and an aseptic non-touch technique are essential. Once access has been obtained, the cannula is secured and checked before the infusion begins.
A well-run service should explain what the patient may feel during cannulation and ensure they are comfortable and appropriately positioned. Discomfort, bruising or an unsuccessful first attempt can occur with any peripheral cannula. Repeated attempts should be considered carefully, particularly where venous access is difficult, rather than treated as a routine inconvenience.
NAD is generally administered gradually. The rate is a significant part of the protocol because some people experience unpleasant sensations if the infusion is delivered too quickly. Depending on the individual and the service’s protocol, the practitioner may begin at a lower rate and adjust it only if the patient remains comfortable and clinically well.
Why rate and monitoring matter
There is no single universal NAD infusion duration that is right for every person. The dose, dilution and infusion rate can affect both the length of the appointment and tolerability. A slower infusion may take longer, but it can be the more appropriate choice where a patient develops symptoms. Faster is not inherently better, and it should not be presented as a marker of treatment strength or quality.
During the infusion, the patient should be able to communicate easily with the practitioner. Some people may report temporary nausea, warmth, headache, abdominal discomfort or a feeling of chest tightness. These symptoms need a clinical response, not reassurance alone. The practitioner may slow or pause the infusion, reassess the patient and decide whether it is appropriate to continue.
Any concerning symptom, including chest pain, significant breathlessness, faintness, swelling around the cannula site or signs of an allergic reaction, requires prompt assessment. The infusion should be stopped where indicated, and the clinic should have clear escalation procedures, emergency equipment and staff trained to respond to deterioration. Patients should never be encouraged to tolerate severe or worrying symptoms in pursuit of a planned dose.
The cannula site also requires regular observation. Pain, redness, swelling, leakage or coolness may indicate infiltration, irritation or phlebitis. Continuing to infuse through a compromised cannula can cause avoidable harm. Safe practice means checking the site throughout treatment and replacing or removing access when necessary.
Completion and aftercare
At the end of the infusion, the practitioner removes the cannula, applies pressure and dresses the site as needed. They should confirm that the patient feels well enough to leave and provide proportionate aftercare advice. This may include keeping the site clean, watching for increasing pain, redness or swelling, and seeking appropriate medical advice if symptoms develop after leaving.
The record should be completed promptly, including the patient’s tolerance of the infusion and any action taken. If an adverse reaction occurs, it should be managed, documented and reviewed through the clinic’s incident procedures. Depending on the event and the product involved, further reporting obligations may apply.
For patients, practical planning is sensible. Allow enough time for the appointment, eat and drink normally unless given different clinical advice, and tell the practitioner about changes in health or medication since the assessment. Whether someone can drive afterwards depends on how they feel, any symptoms experienced and the clinician’s advice. It should not be assumed that every patient will have the same recovery experience.
What to expect from a responsible NAD provider
The quality of NAD infusion care is defined less by a menu of wellness claims and more by the standard of clinical governance behind it. Before booking, patients should expect clear answers on several points:
- who assesses suitability and who administers the infusion;
- how prescribing, product sourcing and traceability are managed where relevant;
- what monitoring takes place during treatment;
- how the clinic responds to side effects, complications and emergencies; and
- what evidence and limitations are discussed before consent.
For clinic operators, written protocols should support, rather than replace, professional judgement. Staff need training in venepuncture or cannulation, infection prevention, recognising adverse reactions, basic life support and escalation procedures appropriate to their role. Governance should include audit, incident review, consent processes and appropriate record keeping.
An NAD infusion should feel unhurried and clinically supervised. The right provider will make room for questions, adjust or stop treatment when needed, and place patient safety above completing a pre-set protocol.